Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Introduction: Idecabtagene vicleucel (ide-cel) was the first FDA approved BCMA targeted CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma (RRMM). However, clinical trials are highly selective with stringent eligibility criteria. The objective of this study was to evaluate...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.1027-1027
Hauptverfasser:	Sidana, Surbhi, Ahmed, Nausheen, Akhtar, Othman S, Heim, Michael, Brazauskas, Ruta, Hansen, Doris K., Ferreri, Christopher, Freeman, Ciara Louise L., Afrough, Aimaz, Anderson, Larry D., Dhakal, Binod, Dhanda, Devender, Gowda, Lohith, Hashmi, Hamza, Harrison, Melanie, Kitali, Amani, Mirza, Sayeef, Patel, Jinalben, Patwardhan, Pallavi, Usmani, Saad Z, Patel, Krina K., Ganguly, Siddhartha, Pasquini, Marcelo
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!